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Objectives: This study aimed to explore associations of lysophosphatidylcholines (LPCs) in 
early pregnancy with gestational diabetes mellitus (GDM), and whether LPCs mediated the 
associations of bile acids with GDM risk or had interactive effects with bile acids on GDM risk.
Design: We conducted a 1:1 nested case-control study (n = 486) from a large prospective pregnant 
women cohort in urban Tianjin, China. Blood samples were collected at their first antenatal care 
visit (median at 10th gestational week). LPCs were measured by liquid chromatography-tandem 
mass spectrometry analysis. Conditional binary logistic regression and restricted cubic spline 
analysis were used to identify cutoff points of these metabolites for GDM risk.
Results: Of the 6 detectable LPCs, LPC14:0 less than 0.24 nmol/mL, LPC15:0 at 0.45 nmol/mL or 
greater, and LPC18:0 at 18.00 nmol/mL or greater were independently associated with GDM risk. 
Adjustment for LPC18:0 slightly attenuated odds ratios (ORs) of deoxycholic acid (DCA, ≤ 0.36 nmol/
mL) and glycoursodeoxycholic acid (GUDCA, ≤ 0.07 nmol/mL) for GDM, and the correlations of DCA 
and GUDCA with LPC18:0 were weak. However, the presence of DCA at 0.36 nmol/mL or less greatly 
amplified the adjusted OR of LPC18:0 at 18.00 nmol/mL or greater alone for GDM from 8.18 (2.51-
26.7) up to 17.7 (6.64-47.1), with significant additive interaction. Similarly, the presence of GUDCA at 
0.07 nmol/mL or less also greatly amplified the adjusted OR of LPC18:0 at 18.00 nmol/mL or greater 
alone for GDM from 17.2 (1.77-168) up to 73.8 (12.7-429), with significant additive interaction.
Conclusions: LPCs in early pregnancy were associated with GDM risk. Low DCA or GUDCA 
greatly amplified the effect of high LPC18:0 on GDM, and its molecular mechanism is worth 
further investigations. (J Clin Endocrinol Metab 105: e982–e993, 2020)
Key Words:  bile acids, Chinese women, gestational diabetes mellitus, lysophosphatidylcholines, 
metabolism
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The International Diabetes Federation has estimated that about 20.4 million women had hyperglycemia 
during pregnancy in 2019, with 83.6% of cases being 
gestational diabetes mellitus (GDM) (1). GDM increases 
risks of both short-term and long-term health outcomes 
in mothers and their offspring (2, 3). Lifestyle interven-
tion can reduce GDM risk by 20% if initiated within 15 
gestational weeks, but are generally ineffective if initi-
ated after the 15th gestational week (4). Hence, it is crit-
ically important to explore novel biomarkers of GDM 
in early pregnancy for a better understanding of the eti-
ology of GDM, as well as identifying at-risk women for 
effective intervention.
Lysophosphatidylcholines (LPCs), a class of lipid bio-
molecules, play important roles in several physiological 
processes, such as vascular development, reproduction, 
and myelination (5). Besides the function of membrane 
phospholipid metabolites, their role as intracellular 
signal molecules is increasingly appreciated, including 
regulating cellular proliferation, inflammation, and 
tumor cell invasion (6, 7). Increasing evidence suggests 
that abnormal LPC levels are associated with many dis-
eases, including diabetes, cardiovascular diseases, and 
cancers (8-10). However, findings from those lipidomics 
studies were inconsistent. For example, a study found 
that plasma LPCs were positively associated with the 
risk of diabetes (11), but another study showed that 
plasma LPCs were inversely associated with diabetes risk 
(12). Our group reported that decreased bile acids, i.e., 
deoxycholic acid (DCA) and glycoursodeoxycholic acid 
(GUDCA), were independently associated with the risk 
of GDM (13). In this connection, several metabolomics 
studies found that abnormal bile acid metabolism was 
associated with phospholipid disorders and both of 
them can be used as biomarkers of diabetes (14, 15). An 
animal study further showed that increased bile acids 
might improve high-fat diet–induced diabetes by re-
ducing LPC, phosphatidycholine, sphingomyeline, and 
ceramide levels (16). Therefore, LPCs are more likely 
to lie downstream of bile acids. However, it remains 
unknown how bile acids and LPCs work together to 
increase the risk of GDM. There are two possibilities 
about the working patterns of DCA/GUDCA and LPCs 
for GDM. One is that low DCA/GUDCA increases 
GDM risk via increasing levels of LPCs. The other is 
that low DCA/GUDCA enhances the effect of LPCs 
on GDM, that is, there is an interactive effect of DCA/
GUDCA and LPCs on GDM risk.
Using a nested case-control study within a pro-
spective population-based cohort of pregnant women in 
Tianjin, China, we aimed to explore 1) the associations 
between LPCs in early pregnancy and the risk of GDM; 
2) whether LPCs mediated the association of low DCA/
GUDCA with GDM risk or had an interactive effect 
with low DCA/GUDCA on the risk of GDM; and 3) the 
predictive values of LPCs for GDM.
Materials and Methods
Study design and participants
The study design, participants, and methods of this pro-
spective cohort have been described in detail previously (17). 
Briefly, 22 302 pregnant women were recruited through the 
universal GDM screening and management system from the 
6 central urban districts of Tianjin, China, between October 
2010 and August 2012. This study was approved by the ethics 
committee of Tianjin Women and Children’s Health Center 
(TWCHC) and written informed consent was obtained from 
all participants before data collection.
A two-step procedure was used to identify GDM among 
pregnant women. First, pregnant women at the 24th to 28th 
weeks of pregnancy were offered a 50-g, 1-hour glucose chal-
lenge test (GCT) in a nonfasting status at a primary care hos-
pital close to their residence. Then, pregnant women with GCT 
greater than or equal to 7.8 mmol/L were referred to TWCHC 
for a 75-g, 2-hour oral glucose tolerance test (OGTT) after 
at least an 8-hour fasting status. GDM was diagnosed by 
the International Association of Diabetes and Pregnancy 
Study Group’s criteria: meeting fasting plasma glucose (PG) 
5.1 mmol/L or greater, 1-hour PG 10.0 mmol/L or greater, or 
2-hour PG 8.5 mmol/L or greater (18).
The selection procedure of the nested case-control study has 
been published in a previous study (13). In brief, 2991 women 
were enrolled and provided overnight fasting venous blood sam-
ples at their first antenatal care visit (median [interquartile range]: 
10 [9-11] gestational weeks). Among them, we excluded 227 
women without GCT results or OGTT results if their GCT was 
7.8 mmol/L or greater at the 24th to 28th gestational weeks. In 
the remaining 2764 women, 243 women who developed GDM 
during pregnancy were selected as the cases and 243 women 
without GDM were selected as the controls matched by maternal 
age (±1 year). The 1:1 nested case-control study (n = 486) was 
used to address our research questions in the current study.
Data collection procedures
All nurses or obstetricians were trained in a series of work-
shops before the fieldwork to standardize all the procedures. 
Data were collected using a series of questionnaires or re-
trieved from the medical records at the first antenatal care 
visit and GCT time till postpartum. Information on maternal 
characteristics included maternal age, height, weight, gesta-
tional weeks, systolic blood pressure (SBP), diastolic blood 
pressure (DBP), nationality, education attainment, parity, per-
sonal or family history of diabetes, current smoker before or 
during pregnancy, alcohol drinker before or during pregnancy, 
etc. Prepregnancy body mass index (BMI) was calculated as 
weight in kilograms at the first antenatal care visit divided by 
the squared height in meters and categorized as underweight 
(< 18.5 kg/m2), normal weight (≥ 18.5 to < 24 kg/m2), over-
weight (≥ 24 to < 28 kg/m2) and obesity (≥ 28 kg/m2) according 
to the criteria of the Working Group on Obesity in China (19). 
Weight gain to GCT was calculated as the difference of body 
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weight divided by the difference of gestational weeks between 
the first registration and GCT time.
Measurement of plasma lysophosphatidylcholines
Sample pretreatment. Each blood sample was separated 
from the venous blood immediately and stored at –80°C until 
used. Stored plasma was thawed at 4°C. Each sample (10 μL) 
was mixed with an internal standard solution (10 μL), 0.9% 
NaCl (10 μL), and chloroform:methanol (2:1) (100 μL). The 
mixture was vortexed for 20 seconds, and then stood at 4°C 
for 30 minutes. After being centrifuged at 7800 g for 3 min-
utes, 20 μL of the supernatant was transferred and concen-
trated to dry under nitrogen. Before being injected for liquid 
chromatography–tandem mass spectrometry analysis, the 
dried supernatant was dissolved with acetonitrile:isopropanol 
(1:1) (20 μL) and vortexed for 60 seconds.
Liquid chromatography–tandem mass spectrometry 
analysis. The LPC components were identified and quantified 
using Eksigent Ultra liquid chromatography 100 coupled with 
a Triple TOF 5600 system (AB SCIEX), and separated using 
a 2.1 × 100mm XBridge Peptide BEH C18 column (Waters) 
with a 4 × 2.0mm guard column (Phenomenex). The separ-
ation of LPCs was achieved under a column temperature of 
40°C using ammonium acetate (10 mM), formic acid (0.1%), 
and water (99.9%) as mobile phase A, and ammonium acetate 
(10 mM), formic acid (0.1%), acetonitrile (49.95%) and iso-
propanol (49.95%) as mobile phase B. The step gradient was 
as follows: 0.01 min, 35% (v/v) B; 0.01 to 2 minutes, 35% 
to 80% (v/v) B; 2 to 9 minutes, 80% to 100% (v/v) B; 9 to 
15 minutes, 100% (v/v) B; 15 to 16 minutes, 100% to 35% 
(v/v) B; 16 to 20 minutes, 35% (v/v) B. The injection volume 
was 2 μL and the total run time was 20 minutes at a flow rate 
of 0.4 mL/min. The parameters, under a negative model, were 
set as follows: curtain gas, ion source gas 1, and ion source 
gas 2 at 30, 50, and 50 psi, respectively; source temperature at 
550°C and ion spray voltage floating at –4500 V. In automatic 
information-dependent acquisition, the m/z range for time of 
flight mass spectrometry scan and production of ion scan were 
100 to 1200 Da and 50 to 1200 Da, respectively. The collision 
energy of the production ion scan was set at –35 ± 15 V and 
the declustering potential was set at –80 V.
Data processing. The Peak View 1.2 was used to identify 
LPCs, and Multi Quant 2.1 was used to quantity LPCs based 
on the m/z value and sample retention time.
Measurement of plasma bile acids
The detailed measurement method of bile acids has been 
described previously (13). Briefly, Eksigent ultral liquid chro-
matography 100 coupled with a Triple TOF 5600 system (AB 
SCIEX), and a 2.1 × 100mm XBridge Peptide BEH C18 column 
(Waters) with a 4 × 2.0mm guard column (Phenomenex) were 
used to quantify plasma bile acids.
Statistical analysis
All statistical analyses were performed using Statistical 
Analysis System Release 9.4 (SAS Institute Inc, Cary, NC, 
USA), unless specified. A  two-tailed P value less than .05 
was considered to be statistically significant. A Q-Q plot was 
used to test the normal distribution of continuous variables. 
Differences between the GDM and non-GDM group were 
compared using a paired Student t  test for the continuous 
variables with normal distribution, Wilcoxon signed-rank test 
for the continuous variables without normal distribution, and 
McNemar test or Fisher exact test for categorical variables.
Restricted cubic spline analysis nested in conditional 
binary logistic regression was used to examine the full-range 
associations of LPCs with the risk of GDM in univariate and 
multivariable analyses. Continuous LPCs were stratified into 
categorical variables at the points where GDM risk started 
to change steeply. A  structured adjustment plan was imple-
mented to control for potential confounding factors. First, we 
performed conditional logistic regression to obtain the un-
adjusted odds ratio (OR) and 95% CI. Second, we adjusted 
for traditional risk factors including prepregnancy BMI, SBP, 
nationality, family history of diabetes in first-degree relatives, 
parity, education attainment, current smoker and alcohol 
drinker before pregnancy, and weight gain from registration 
to GCT. Finally, we performed a stepwise forward selection in 
the conditional logistic regression to identify LPC species that 
had effects on GDM risk independent of these traditional risk 
factors (P < .05 for entry and exit).
In addition, the mediating effect of LPCs on the associ-
ation of low DCA/GUDCA on GDM risk was tested by the 
change in ORs of DCA/GUDCA for GDM before and after 
adjustment for particular LPC species. The separating point 
of DCA/GUDCA before and after the adjustments was used 
to recategorize DCA/GUDCA as we did before (20). Partial 
Spearman correlation analysis was used to test correlations 
between bile acids and LPCs while adjusting for maternal 
age and prepregnancy BMI. Additive interaction was used 
to test interactive effects between low DCA/GUDCA and 
high LPC species at the selected cutoff points for GDM. 
Significant relative excess risk due to interaction greater than 
0, attributable proportion due to interaction (AP) greater 
than 0 or synergy index greater than 1 suggested an addi-
tive interaction (21). Finally, a receiver operating character-
istic (ROC) curve was used to check whether the inclusion 
of LPCs was able to increase the predictive value for GDM, 
with inclusion of traditional risk factors only and traditional 
risk factors plus DCA and GUDCA.
Results
Characteristics of the study participants
Clinical and biomedical characteristics of the 
participating pregnant women are shown in Table 1. The 
mean age of participants was 29.2 years (SD, 3.1 years)
and the median gestational age at first registration was 
10 weeks (interquartile range, 9-11 weeks). There were 
no significant differences in body height, gestational 
age at registration, nationality, education attainment, 
parity, current smoker and alcohol drinker before or 
during pregnancy, and weight gain from registration to 
GCT between GDM and non-GDM groups. However, 
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women with GDM had higher BMI, SBP/DBP, and GCT 
glucose levels. The percentage of women with a family 
history of diabetes in a first-degree relative was also 
higher in the GDM group than in the non-GDM group. 
The levels of LPC egg, LPC15:0, LPC17:0, LPC18:0, 
and LPC18:1 were higher in the GDM group compared 
to the non-GDM group, whereas LPC14:0 was similar 
in both groups.
Associations of lysophosphatidylcholines with 
gestational diabetes mellitus
LPC egg, LPC15:0, LPC17:0, LPC18:0, and LPC18:1 
were positively associated with GDM risk in a nonlinear 
manner with clear threshold effects (Fig.  1). LPC egg 
at 95.00 nmol/mL or greater, LPC15:0 at 0.45 nmol/mL 
or greater, LPC17:0 at 0.80 nmol/mL or greater, LPC18:0 
at 18.00 nmol/mL or greater, and LPC18:1 at 4.50 nmol/
mL or greater were associated with increased risk of 
GDM in univariate and multivariable analyses (Table 2). 
LPC14:0 was associated with GDM risk in a U-shaped 
manner. Using 0.24 to 0.42 nmol/mL as the reference, 
LPC14:0 less than 0.24 nmol/mL was inversely associ-
ated with GDM risk in univariate and multivariable ana-
lyses, but LPC14:0 at 0.42 nmol/mL or greater for GDM 
was no longer significant in multivariable analysis. The 
stepwise selection procedure identified that LPC14:0 
less than 0.24 nmol/mL, LPC15:0 at 0.45 nmol/mL or 
greater, and LPC18:0 at 18.00 nmol/mL or greater were 
significantly associated with increased risk of GDM, in-
dependent of traditional risk factors (OR of LPC14:0: 
3.85, 95% CI: 1.50-9.84; LPC15:0: 3.55, 1.15-10.9; and 
LPC18:0: 18.8, 7.88-44.7).
Table 1. Clinical and biochemical characteristics of GDM and non-GDM women
Characteristic Non-GDM (N = 243) GDM (N = 243) P
Variables at registration    
age, y 29.2 ± 3.3 29.2 ± 2.7 –
height, cm 163.2 ± 4.6 163.1 ± 5.0 .28a
Weight, kg 58.2 ± 9.6 63.7 ± 10.5 < .001a
BMi, kg/m2 21.8 ± 3.4 23.9 ± 3.6 < .001a
BMi in category   < .001b
 ≥ 24.0 to < 28.0 45 (18.5) 77 (31.7)  
 ≥ 28.0 12 (4.9) 31 (12.8)  
Gestational age, wks 10.1 ± 2.0 10.1 ± 2.1 .94a
systolic blood pressure, mm hg 104.0 ± 10.5 108.3 ± 10.5 < .001a
Diastolic blood pressure, mm hg 67.9 ± 7.7 70.6 ± 8.0 < .001a
han nationality 234 (96.3) 238 (98.0) .29b
education > 12 y 132 (54.3) 135 (55.6) .78b
Parity ≥ 1 12 (4.9) 14 (5.8) .68b
Family history of diabetes in first-degree relatives 14 (5.8) 30 (12.4) .01b
Current smoker before pregnancy 9 (3.7) 10 (4.1) .81b
alcohol drinker before pregnancy 57 (23.5) 72 (29.6) .12b
lPC species    
lPC egg, nmol/ml 76.77 (62.41-97.32) 125.80 (97.55-157.59) < .001a
 ≥ 95.00 63 (25.93) 187 (76.95) < .001b
lPC14:0, nmol/ml 0.21 (0.17-0.28) 0.20 (0.16-0.30) .85a
 < 0.24 84 (34.57) 59 (24.28) .05b
 ≥ 0.24 to < 0.42 143 (58.85) 157 (64.61)  
 ≥ 0.42 16 (6.58) 27 (11.11)  
lPC15:0, nmol/ml 0.32 (0.28-0.39) 0.37 (0.30-0.48) < .001a
 ≥ 0.45 30 (12.35) 69 (28.40) < .001b
lPC17:0, nmol/ml 0.70 (0.52-0.93) 1.03 (0.79-1.31) < .001a
 ≥ 0.80 89 (36.63) 178 (73.25) < .001b
lPC18:0, nmol/ml 13.06 (10.76-17.19) 22.77 (19.02-28.93) < .001a
 ≥ 18.00 52 (21.40) 199 (81.89) < .001b
lPC18:1, nmol/ml 4.19 (3.50-5.29) 5.84 (4.89-7.19) < .001a
 ≥ 4.50 101 (41.56) 202 (83.13) < .001b
Variables during pregnancy    
Current smoker during pregnancy 1 (0.4) 2 (0.8) 1.00b
alcohol drinker during pregnancy 2 (0.8) 2 (0.8) 1.00b
Weight gain to GCt, kg/wk 0.6 ± 0.2 0.6 ± 0.2 .16a
GCt glucose, mmol/l 6.3 (5.4-7.2) 9.0 (8.4-10.0) < .001a
Data are reported in mean ± sD or number (percentages) or median (25th-75th percentile).
abbreviations: BMi, body mass index; GCt, glucose challenge test; GDM, gestational diabetes mellitus; lPC, lysophosphatidylcholine.
aDerived from paired t test or Wilcoxon signed-rank test.
bDerived from Mcnemar test or Fisher exact test.
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Mediating effects of lysophosphatidylcholines on 
associations between bile acids and gestational 
diabetes mellitus risk
Adjustment for LPC18:0 slightly attenuated the ef-
fects of low DCA (≤ 0.36  nmol/mL) and low GUDCA 
(≤ 0.07  nmol/mL) on GDM risk (Table  3 and Fig.  2). 
Using the two cutoff points, the OR of DCA less than 
or equal to vs greater than 0.36  nmol/mL for GDM 
was reduced from 2.09 (1.27-3.46) before adjustment 
for LPC18:0 to 1.29 (0.62-2.67) after the adjustment. 
? ?
Figure 1. the association of individual lysophosphatidylcholines (lPCs) with gestational diabetes risk. the dotted (black, bottom) lines were 
derived from univariate analyses, the crossed (blue, upper) lines were derived from multivariable analyses with adjustment for traditional risk 
factors, included prepregnancy body mass index, systolic blood pressure, han-nationality, family history of diabetes in first-degree relatives, parity, 
education attainment, current smoker before pregnancy, alcohol drinker before pregnancy, and weight gain to glucose challenge test, and the 
straight (red) lines are the reference line at odds ratio equal to 1.
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Similarly, the OR of GUDCA less than or equal to vs 
greater than 0.07  nmol/mL was attenuated by adjust-
ment for LPC18:0 from 6.32 (2.34-17.1) to 4.53 (1.26-
16.3). On the other hand, there were weak correlations 
of LPC18:0 with DCA and GUDCA after adjustment 
for maternal age and prepregnancy BMI (Spearman 
correlation coefficients with DCA: –0.1344; Spearman 
correlation coefficients with GUDCA: –0.1971, both 
P values < .05) (Table 4).
Additive interactions between bile acids and 
lysophosphatidylcholines for gestational diabetes 
mellitus
DCA less than or equal to 0.36  nmol/mL alone 
for GDM (0.84, 0.32-2.23) was not significant but 
greatly increased the OR of LPC18:0 greater than 
or equal to 18.00  nmol/mL alone from 8.18 (2.51-
26.7) up to 17.7 (6.64-47.1), that is, for presence of 
both risk factors, with significant additive interaction 
Table 3. Odds ratios of low DCA and GUDCA for risk of GDM mediated by LPCs
OR 95% CI P
Model 1    
 DCa ≤ vs > 0.36, nmol/ml 2.09 1.27-3.46 .004
 GUDCa ≤ vs > 0.07, nmol/ml 6.32 2.34-17.1 < .001
Model 2    
 DCa ≤ vs > 0.36, nmol/ml 2.07 1.24-3.46 .005
 GUDCa ≤ vs > 0.07, nmol/ml 7.63 2.68-21.7 < .001
Model 3    
 DCa≤ vs > 0.36, nmol/ml 1.89 1.13-3.18 .02
 GUDCa ≤ vs > 0.07, nmol/ml 5.31 1.92-14.7 .001
Model 4    
 DCa ≤ vs > 0.36, nmol/ml 1.29 0.62-2.67 .50
 GUDCa ≤ vs > 0.07, nmol/ml 4.53 1.26-16.3 .02
Model 1 was adjusted for traditional risk factors.
Model 2 was adjusted for variables in model 1 and level of lPC14:0.
Model 3 was adjusted for variables in model 1 and level of lPC15:0.
Model 4 was adjusted for variables in model 1 and level of lPC18:0.
abbreviations: DCa, deoxycholic acid; GDM, gestational diabetes mellitus; GUDCa, glycoursodeoxycholic acid; lPC, lysophosphatidylcholine; OR, 
odds ratio.
Table 2. Odds ratios of LPCs for risk of GDM
Unadjusted Adjusteda
 OR (95% CI) P OR (95% CI) P
step 1b     
lPC egg ≥ vs < 95.00, nmol/ml 7.53 (4.66-12.2) < .001 8.55 (4.75-15.4) < .001
lPC14:0, nmol/ml     
 < 0.24 1.53 (1.03-2.29) .04 1.93 (1.16-3.23) .01
 ≥ 0.24 to < 0.42 (Reference)  (Reference)  
 ≥ 0.42 2.53 (1.19-5.35) .02 2.37 (1.00-5.66) .05
lPC15:0 ≥vs <0.45, nmol/ml 3.05 (1.82-5.13) < .001 3.40 (1.87-6.21) < .001
lPC17:0 ≥ vs < 0.80, nmol/ml 5.68 (3.49-9.26) < .001 6.15 (3.43-11.0) < .001
lPC18:0 ≥ vs < 18.00, nmol/ml 15.7 (8.29-29.8) < .001 16.4 (7.89-34.0) < .001
lPC18:1 ≥ vs < 4.50, nmol/ml 6.61 (4.03-10.9) < .001 7.84 (4.28-14.4) < .001
step 2c     
lPC14:0, nmol/ml     
 < 0.24 1.96 (1.00-3.82) .05 3.85 (1.50-9.84) .005
 ≥ 0.24 to < 0.42 (Reference)  (Reference)  
 ≥ 0.42 0.58 (0.18-1.85) .36 0.27 (0.06-1.14) .07
lPC15:0 ≥ vs < 0.45, nmol/ml 2.29 (0.98-5.32) .06 3.55 (1.15-10.9) .03
lPC18:0 ≥ vs < 18.00, nmol/ml 15.0 (7.65-29.5) < .001 18.8 (7.88-44.7) < .001
abbreviations: GDM, gestational diabetes mellitus; lPC, lysophosphatidylcholine; OR, odds ratio.
atraditional risk factors adjusted in the multivariable analysis included prepregnancy body mass index, systolic blood pressure, han nationality, family 
history of diabetes in first-degree relatives, parity, education attainment, current smoker before pregnancy, alcohol drinker before pregnancy, weight 
gain to glucose challenge test, in addition to the variables listed in the model.
bUnivariate and multivariable odds ratios of individual lPC for the risk of GDM.
cstepwise regression was performed to identify lPC species that had effects on GDM risk independent of these traditional risk factors (P < .05 for 
entry and exit).
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(AP: 0.55, 0.05-1.05). In the same vein, GUDCA less 
than or equal to 0.07 nmol/mL alone for GDM (4.75, 
0.90-25.0) was also not significant but it greatly in-
creased the OR of LPC18:0 greater than or equal to 
18.00  nmol/mL alone from 17.2 (1.77-168) to 73.8 
(12.7-429), that is, for presence of both risk fac-
tors, with a significant additive interaction (AP: 0.72, 
0.29-1.14) (Table 5).
Figure 2. the association of deoxycholic acid (DCa)/glycoursodeoxycholic acid (GUDCa) with gestational diabetes mediated by species 
lysophosphatidylcholine (lPC). the dotted (black, upper) lines were derived from multivariable analyses with adjustment for traditional risk factors, 
the crossed (blue, bottom) lines were derived from multivariable analyses with adjustment for traditional risk factors plus individual lPC (a, plus 
lPC14:0; B, plus lPC15:0; C, plus lPC18:0), and the straight (red) lines are the reference line at odds ratio equal to 1.
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Predictive values of lysophosphatidylcholines for 
gestational diabetes mellitus
Inclusion of LPCs, that is, LPC14:0, LPC15:0, and 
LPC18:0, markedly improved the prediction of GDM. 
The area under the curve (AUC) increased from 0.69 
(0.64-0.74) for the model incorporating only traditional 
risk factors to 0.87 (0.84-0.90) (P < .001). Similarly, in-
clusion of these LPCs also increased the AUC of a model 
including traditional risk factors plus bile acids (DCA 
and GUDCA) from 0.75 (0.70-0.79) to 0.88 (0.85-0.92) 
(P < .001) (Fig. 3).
Discussion
In this nested case-control study, we found that LPC14:0 
less than 0.24 nmol/mL, LPC15:0 greater than or equal 
to 0.45 nmol/mL, and LPC18:0 greater than or equal to 
18.00 nmol/mL in early pregnancy were independently 
associated with increased GDM risk. LPC18:0 had 
weak correlations with DCA and GUDCA and adjust-
ment for high LPC18:0 slightly attenuated the effects 
of low DCA and GUDCA on risk of GDM, whereas 
there was a significant additive interaction between 
Table 5. Additive interaction between DCA or GUDCA and LPC18:0 for risk GDM
Unadjusteda Adjustedb
 OR/Estimate (95% CI) P OR/Estimate (95% CI) P
DCa and lPC18:0  
additive interaction models
    
DCa > 0.36 and lPC18:0 < 18.00 (Reference)  (Reference)  
DCa > 0.36 and lPC18:0 ≥ 18.00 8.19 (2.99 to 22.4) < .001 8.18 (2.51 to 26.7) < .001
DCa ≤ 0.36 and lPC18:0 < 18.00 0.83 (0.35 to 1.95) .67 0.84 (0.32 to 2.23) .73
DCa ≤ 0.36 and lPC18:0 ≥ 18.00 16.8 (7.22 to 39.2) < .001 17.7 (6.64 to 47.1) < .001
Measures of additive interactionc     
 ReRi 8.81 (–2.84 to 20.5) – 9.67 (-4.97 to 24.3) –
 aP 0.52 (0.09 to 0.96) – 0.55 (0.05 to 1.05) –
 s 2.26 (0.81 to 6.26) – 2.38 (0.69 to 8.22) –
GUDCa and lPC18:0  
additive interaction models
    
GUDCa > 0.07 and lPC18:0 < 18.00 (Reference)  (Reference)  
GUDCa > 0.07 and lPC18:0 ≥ 18.00 12.0 (1.78 to 81.5) .01 17.2 (1.77 to 168) .01
GUDCa ≤ 0.07 and lPC18:0 < 18.00 5.01 (1.10 to 22.8) .04 4.75 (0.90 to 25.0) .07
GUDCa ≤ 0.07 and lPC18:0 ≥ 18.00 79.1 (16.3 to 383) < .001 73.8 (12.7 to 429) < .001
Measures of additive interactionc     
 ReRi 63.0 (–41.2 to 167) – 52.8 (–50.2 to 156) –
 aP 0.80 (0.57 to 1.03) – 0.72 (0.29 to 1.14) –
 s 5.19 (1.56 to 17.2) – 3.64 (0.76 to 17.5) –
abbreviations: aP, attributable proportion due to interaction; DCa, deoxycholic acid; GUDCa, glycoursodeoxycholic acid; lPC, lysophosphatidylcholine; 
OR, odds ratio; ReRi, relative excess risk due to interaction; s, synergy index.
anot adjusted for any other variables.
badjusted for traditional risk factors.
cstatistically significant, with ReRi greater than 0, aP greater than 0, or s greater than 1 indicating significant additive interaction.
Table 4. Spearman correlation coefficients of bile acids for LPCs
DCA GUDCA
 Correlation Coefficient P Correlation Coefficient P
Univariate analysisa     
 lPC14:0 0.0618 .18 –0.0752 .10
 lPC15:0 0.0309 .50 –0.1611 < .001
 lPC18:0 –0.1359 .003 –0.2150 < .001
Multivariable analysisb     
 lPC14:0 0.0779 .09 –0.0706 .13
 lPC15:0 0.0504 .28 –0.1665 < .001
 lPC18:0 –0.1344 .004 –0.1971 < .001
abbreviations: DCa, deoxycholic acid; GUDCa, glycoursodeoxycholic acid; lPC, lysophosphatidylcholine.
anot adjusted for any other variables.
badjusted for maternal age and prepregnancy body mass index.
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low DCA/GUDCA and high LPC18:0, that is, low 
DCA/GUDCA greatly amplified the risk association of 
LPC18:0 with GDM.
Some small studies have previously investigated the 
associations between unsaturated LPCs and GDM risk. 
For example, Zhao et al conducted a 1:1 case-control 
study (n  =  214) during the first and second trimester 
of pregnancy and observed that the LPC20:4 ratios 
of second trimester to first trimester were significantly 
lower in GDM women than in control women, sug-
gesting a role of abnormal LPCs metabolism in the 
etiology of GDM (22). Dudzik and colleagues also 
conducted a 1:1 case-control study (n  =  40) during 
the second trimester of pregnancy and reported that 
LPC18:1, LPC18:2, and LPC20:5 were lower in women 
with GDM, with LPC18:2 having the best correl-
ation with glycemic status of pregnant women (23). 
A few earlier studies have shown that plasma LPCs in 
early pregnancy, particularly saturated LPCs, play a 
role in GDM. In this case-control study with a larger 
sample size nested in a large cohort, we found that low 
LPC14:0, high LPC15:0, and, especially, high LPC18:0 
in early pregnancy, had large and independent effects on 
the risk of GDM.
The mechanism underlying the roles of LPCs in the eti-
ology of GDM remains elusive. Several lines of evidence 
support the pathway from decreased DCA/GUDCA 
to increased LPC18:0 could play a role in the etiology 
of GDM. First, a biological link between decreased 
DCA/GUDCA and increased LPC18:0 is plausible. In 
a study of transgenic mice overexpressing cholesterol 
7α-hydroxylase (CYP7A1-tg mice), it was shown that 
increasing intestinal tauro-β-muricholic acid, an antag-
onist of the farnesoid X receptor (FXR), may reduce 
a high-fat diet–induced increase in LPCs, possibly via 
inhibiting activity of the FXR (16). In this regard, an-
other study revealed that GUDCA was an intestinal 
FXR antagonist and biological links of gut microbiota-
GUDCA-FXR to glucose intolerance (24). Hence, a pos-
sibility is that low GUDCA can increase the synthesis of 
LPCs via activity of the FXR. Second, findings from sev-
eral mechanistic investigations support that high LPCs 
were associated with insulin resistance and abnormal 
glucose metabolism. In this connection, higher levels of 
Figure 3. Receiver operating characteristic curves of traditional risk factors, bile acids (Bas) plus lysophosphatidylcholines (lPCs) for gestational 
diabetes in Chinese pregnant women. Bas include deoxycholic acid and glycoursodeoxycholic acid. lPCs include lPC14:0, lPC15:0 and lPC18:0. 
the blue (dash, bottom) curve for the traditional risk factors model (model 1), the purple (dashed dot, midbottom) curve for the traditional risk factors 
plus Bas model (model 2), the green (dot, midupper) curve for the traditional risk factors plus lPCs model (model 3), and the black (solid, upper) curve 
for the traditional risk factors plus Bas and lPCs model (model 4). the area under curve of those 4 models was 0.69 (95% Ci: 0.64-0.74), 0.75 (0.70-
0.79), 0.87 (0.84-0.90), and 0.88 (0.85-0.92), respectively. P values were less than .001 between model 1 and model 3, between model 2 and model 
3, as well as between model 2 and model 4, and .04 between model 3 and model 4.
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LPCs in hepatocytes can upregulate genes of triglyceride 
biosynthesis and downregulate genes of hepatic fatty 
acid oxidation via enhancing cytochrome C release and 
disturbing mitochondrial integrity (25). Increased trigly-
ceride biosynthesis and decreased fatty acid oxidation 
were both associated with GDM risk (22, 26). Higher 
LPCs can increase the release of interleukin-1β (IL-1β), 
IL-6, and tumor necrosis factor-α from adipocytes to 
induce proinflammatory effects that also increased the 
risk of GDM (27-29). In addition, higher LPCs not only 
can modulate inflammatory chemokine expression from 
endothelical cells involved in the expression of mono-
cyte chemoattractant protein-1, cytotoxicity/apoptosis, 
and production of IL-8 (30, 31), but also increase oxi-
dative stress via inducing the overproduction of nitric 
oxide (32). Increased inflammation and oxidative stress 
may lead to increased GDM risk (33). In this regard, our 
study found that LPC18:0 only slightly attenuated the 
effects of DCA and GUDCA on the risk of GDM, and 
the correlations of DCA and GUDCA with LPC18:0 
were quite weak. The weak correlations suggest that 
LPC18:0 is unlikely to be the direct downstream mol-
ecules of DCA/GUDCA. On the other hand, our study 
also found there was a significant additive interaction 
between low DCA/GUDCA and high LPC18:0 for GDM 
risk. The observation supports that low DCA/GUDCA 
is more likely to play an enhancing role but does not 
increase the risk of GDM via directly increasing levels 
of LPC18:0.
It is biologically plausible for low DCA/GUDCA to 
play an enhancing role in the link between LPC18:0 and 
GDM. One possibility is that low DCA/GUDCA and 
high LPC 18:0 work synergistically on downstream mo-
lecular pathways, such as the C-Jun N-terminal kinase 
pathway (34), to increase the risk of GDM. The second 
possibility is that low DCA/GUDCA enhances the risk 
association between LPC18:0 and GDM via increasing 
levels of upstream molecules. In this regard, LPCs were 
reported to act as a second signal activator and may 
mediate free fatty acid (FFA)-induced insulin resistance 
(34). Thus, it is presumed that decreased DCA/GUDCA 
may further increase levels of FFAs that amplify the ef-
fect of LPC18:0 on inducing insulin resistance. Indeed, 
it is worthwhile to investigate whether FFA and DCA/
GUDCA work in a synergistic manner to increase 
LPC18:0 and consequently to increase the risk of GDM.
Our findings have potential clinical and public 
health implications. The effectiveness of lifestyle modi-
fication for prevention of GDM depends on early ini-
tiation of the intervention (4). It is crucial to identify 
women at high risk of GDM in early pregnancy. The 
major strength of this study was that pregnant women 
who provided blood samples were recruited from early 
pregnancy (median at the 10th gestational week) much 
earlier than GCT and OGTT (at the 24th-28th gesta-
tional weeks), and that further suggests the effect of 
causation that metabolic changes lead to GDM. In 
addition, our results also showed that the inclusion of 
LPCs in models incorporating traditional risk factors 
greatly increased AUC from 0.69 to 0.87, suggesting 
that GDM is highly predictable using LPCs in early 
pregnancy.
This study had several limitations. First, the signifi-
cance of our findings was in part dependent on the 
causal relationship between bile acid concentrations 
and GDM risk. In this regard, we had found that low 
DCA and low GUDCA in early pregnancy were asso-
ciated with increased GDM risk in a previous analysis 
(13). A  mechanistic investigation explored biological 
links of gut microbiota-GUDCA-FXR to glucose in-
tolerance and provided some evidence of a possible 
causal relationship between low GUDCA and glucose 
intolerance (24). Although solid evidence from ran-
domized controlled trials is yet to come, the causal 
associations between low DCA/GUDCA and GDM 
is highly likely. Second, levels of LPC and bile acid 
both can be influenced by dietary habits and our study 
did not collect detailed information on dietary habits 
from pregnant women. However, diet is associated 
with many demographic and clinical factors. In this 
study, we carefully adjusted for potential confounding 
factors, which may have partially removed the con-
founding effect of diet if any. Third, the pregnant 
women in this study were all from urban Tianjin and 
these findings need to be replicated in other Chinese 
and non-Chinese populations.
In conclusion, we found that LPC14:0 less than 
0.24  nmol/mL, LPC15:0 greater than or equal to 
0.45 nmol/mL, and LPC18:0 greater than or equal to 
18.00 nmol/mL were independently associated with in-
creased GDM risk. Furthermore, low DCA/GUDCA had 
a significant additive interaction with high LPC18:0, 
which greatly amplified the effect of high LPC18:0 on 
the risk of GDM. The ROC curve analysis for prediction 
of GDM showed that inclusion of LPCs in the model 
with traditional risk factors greatly increased the AUC 
from 0.69 to 0.87. Thus, our study suggests that risk 
scores with inclusion of LPCs may accurately predict 
GDM in early pregnancy, so early lifestyle interven-
tion can be conducted in a more cost-effective manner. 
Future mechanistic studies need to be undertaken to 
fully understand the underlying molecular mechanisms 
between DCA/GUDCA and LPC18:0 in the etiology 
of GDM.
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